Summary & Overview
HCPCS E0736: Transcutaneous Tibial Nerve Stimulator
HCPCS Level II code E0736 designates a transcutaneous tibial nerve stimulator, a durable medical device used for neuromodulation in patients with lower urinary tract and pelvic floor dysfunction. This code matters nationally as neuromodulation therapies expand as non-invasive alternatives to more invasive procedures and as payers refine coverage and billing rules for durable medical equipment and outpatient neuromodulation services. Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, common billing modifiers, and the payer landscape. The publication summarizes coverage considerations, billing practice themes, and where readers can expect variation across major commercial payers and Medicare. The aim is to clarify what E0736 represents, outline where it is commonly billed, and present the topics clinicians and billing professionals should review when preparing claims or evaluating coverage for transcutaneous tibial nerve stimulation.
Billing Code Overview
HCPCS Level II code E0736 describes a transcutaneous tibial nerve stimulator. This device provides neuromodulation therapy delivered through the skin to the tibial nerve for management of lower urinary tract dysfunction and related pelvic floor conditions. The service type is durable medical equipment / neuromodulation therapy. Typical sites of service include outpatient clinics, urology or urogynecology practices, and home settings where the device may be used for ongoing therapy.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55-year-old individual with refractory overactive bladder symptoms — urinary urgency, frequency, nocturia, and urge incontinence — who has failed behavioral therapies and at least one class of pharmacotherapy. The clinical workflow begins with a urology or urogynecology evaluation documenting symptom history, bladder diary, and prior treatments. After shared decision-making, the clinician schedules a transcutaneous tibial nerve stimulation treatment session using a device billed as E0736 (transcutaneous tibial nerve stimulator). In the office or outpatient clinic, the patient is positioned supine or seated, adhesive surface electrodes are applied posterior to the medial malleolus and on the plantar foot or calf per device instructions, and stimulation parameters are set. Typical treatment consists of 20–30 minute sessions performed weekly for several weeks, with progress documented in the medical record including indication, consent, device settings, duration, response, and any adverse effects. Follow-up visits assess symptom improvement and determine ongoing therapy or transition to alternative interventions such as percutaneous tibial nerve stimulation or sacral neuromodulation. The typical site of service is an outpatient clinic, urology or gynecology office, or ambulatory surgery center when combined with other procedures.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |